JUBILANT PHARMOVA
|
JUBILANT PHARMOVA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 25.22 | 53.13 | 4.88 | -3.84 | 26.01 |
| CEPS(Rs) | 53.03 | 76.26 | 28.77 | 30.76 | 49.93 |
| DPS(Rs) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Book NAV/Share(Rs) | 447.70 | 394.94 | 343.00 | 339.19 | 333.91 |
| Tax Rate(%) | 35.27 | 14.72 | 57.36 | 333.45 | 34.49 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.41 | 15.35 | 13.44 | 12.36 | 18.86 |
| EBIT Margin(%) | 9.44 | 15.97 | 6.61 | 3.44 | 12.66 |
| Pre Tax Margin(%) | 7.02 | 12.83 | 2.54 | 0.44 | 10.28 |
| PAT Margin (%) | 4.55 | 10.94 | 1.08 | -1.03 | 6.74 |
| Cash Profit Margin (%) | 9.58 | 15.76 | 6.78 | 7.79 | 12.96 |
| Performance Ratios | |||||
| ROA(%) | 2.86 | 7.02 | 0.65 | -0.63 | 4.44 |
| ROE(%) | 5.97 | 14.35 | 1.34 | -1.21 | 8.21 |
| ROCE(%) | 8.69 | 13.92 | 5.02 | 2.53 | 9.97 |
| Asset Turnover(x) | 0.63 | 0.64 | 0.60 | 0.61 | 0.66 |
| Sales/Fixed Asset(x) | 0.97 | 0.97 | 0.88 | 0.89 | 0.95 |
| Working Capital/Sales(x) | 5.57 | 5.68 | 3.85 | 3.16 | 3.20 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.03 | 1.03 | 1.14 | 1.12 | 1.05 |
| Receivable days | 40.92 | 43.15 | 51.11 | 54.89 | 52.04 |
| Inventory Days | 49.26 | 57.75 | 72.70 | 76.56 | 70.98 |
| Payable days | 154.52 | 146.59 | 143.02 | 134.99 | 133.47 |
| Valuation Parameters | |||||
| PER(x) | 32.37 | 16.80 | 116.50 | - | 14.91 |
| PCE(x) | 15.40 | 11.71 | 19.76 | 9.07 | 7.77 |
| Price/Book(x) | 1.82 | 2.26 | 1.66 | 0.82 | 1.16 |
| Yield(%) | 0.61 | 0.56 | 0.88 | 1.79 | 1.29 |
| EV/Net Sales(x) | 1.79 | 2.14 | 1.71 | 1.09 | 1.32 |
| EV/Core EBITDA(x) | 11.20 | 12.56 | 11.80 | 8.39 | 6.95 |
| EV/EBIT(x) | 17.98 | 12.66 | 25.83 | 31.63 | 10.46 |
| EV/CE(x) | 1.44 | 1.78 | 1.29 | 0.78 | 0.83 |
| M Cap / Sales | 1.56 | 1.95 | 1.34 | 0.71 | 1.01 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.45 | 7.93 | 6.71 | 2.47 | 0.52 |
| Core EBITDA Growth(%) | 7.74 | 26.92 | 19.03 | -30.24 | -17.43 |
| EBIT Growth(%) | -32.35 | 175.72 | 105.00 | -72.16 | -26.46 |
| PAT Growth(%) | -52.47 | 1,050.34 | 212.02 | -115.71 | -28.03 |
| EPS Growth(%) | -52.53 | 988.73 | 227.19 | -114.75 | -50.48 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.46 | 0.39 | 0.63 | 0.63 | 0.55 |
| Current Ratio(x) | 1.62 | 1.62 | 1.92 | 2.12 | 2.20 |
| Quick Ratio(x) | 1.13 | 1.10 | 1.24 | 1.34 | 1.42 |
| Interest Cover(x) | 3.90 | 5.08 | 1.63 | 1.15 | 5.33 |
| Total Debt/Mcap(x) | 0.25 | 0.17 | 0.38 | 0.77 | 0.47 |
Compare Financial Ratios of peers of JUBILANT PHARMOVA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JUBILANT PHARMOVA | ₹14,868.3 Cr | -4.6% | -5.3% | -20.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,270.0 Cr | -1.5% | 2.5% | 14.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹222,224.0 Cr | 7.4% | 22.2% | 26.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,325.0 Cr | 3.1% | 4.3% | 38.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.6% | -1.4% | -6.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,876.6 Cr | 1.5% | -15.2% | -9.1% | Stock Analytics | |
JUBILANT PHARMOVA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JUBILANT PHARMOVA | -4.6% |
-5.3% |
-20.7% |
| SENSEX | 2.2% |
0.9% |
-3.7% |
You may also like the below Video Courses
